Colorectal Cancer Drugs Global Market Opportunities And Strategies To 2034
상품코드:1880711
리서치사:The Business Research Company
발행일:2025년 11월
페이지 정보:영문 337 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 대장암 치료제 시장은 2024년에 약 129억 5,167만 달러의 규모에 이르렀으며, 2019년 이후 CAGR 6.74%로 계속 성장하고 있습니다. 이 시장은 2024년 129억 5,167만 달러에서 2029년 168억 8,559만 달러로 성장할 전망이며, 5.45%의 성장률로 확대될 것으로 예측됩니다. 그 후 2029년 이후에도 CAGR 5.37%로 성장을 계속해 2034년에는 219억 3,516만 달러에 이를 전망입니다.
대장암 치료제는 결장 또는 직장에서 발생하는 암을 예방, 관리 또는 치료하기 위해 개발된 의약품 치료를 말합니다. 이러한 약물에는 암세포를 표적으로 하고, 질병의 진행을 늦추며, 생존율을 향상시키도록 설계된 다양한 치료 접근법이 포함됩니다. 환자의 치료 성과를 높이는 것으로, 세계적인 대장암의 부담을 경감하는 데 중요한 역할을 하고 있습니다.
제약 업계에서 임상시험 활동 증가
과거에 대장암 치료제 시장은 주로 제약 업계에서 임상시험 활동 증가에 의해 견인되어 왔습니다. 연간 등록되는 임상 연구의 수가 증가 경향에 있으며, 다양한 치료 영역에서 연구 개발 노력의 고조를 반영하고 있습니다. 이 임상시험 활동의 활성화는 유망한 치료법의 견조한 파이프라인을 나타내고 있으며, 역동적이고 확대를 계속하는 제약 업계의 상황을 이야기하고 있습니다. 임상시험 수 증가는 의료과학의 진보 및 미충족 요구에 대응하는 업계의 노력을 뒷받침하는 것입니다. 게다가 임상시험 활동의 확대는 연구기관, 의료 제공자, 규제 당국 간의 연계 강화를 촉진하여 의약품 개발 프로세스의 전반적인 효율성 및 효능을 높이고 있습니다. 예를 들어, 미국 정부가 지원하는 임상 연구 데이터베이스 'ClinicalTrials.gov'에 따르면, 2023년 미국 대륙에 등록된 임상시험은 약 1만 1,974건으로, 이는 전 세계 전체 시험의 12.06%를 차지하고 있습니다. 따라서 제약 업계에서의 임상시험 활동 증가는 해당 기간 대장암 치료제 시장의 성장과 발전에 크게 기여했습니다.
대장암 치료의 바이오시밀러 혁신, 접근성 향상 및 비용 절감
대장암 치료제 시장 진출 기업은 치료에 대한 접근 확대, 치료비 전체 절감, 고가의 생물학적 제제에 대한 대안적인 선택의 제공을 목적으로 바이오시밀러를 개발하고 있습니다. 이들은 기준 의약품과 동등한 안전성, 효능, 품질을 유지하면서 경제적 장벽을 줄임으로써 환자의 치료 계속율 향상을 도모하고 의료 예산이 제약되는 지역에서의 표준 치료의 보급 촉진을 목표로 하고 있습니다. 예를 들어, 2025년 4월에는 인도에 본거를 둔 바이오 의약품 기업인 바이오콘 바이오로직스사가 미국 식품의약품국(FDA)으로부터 전이성 대장암 및 기타 암 치료에 적용되는 베바시주맙 바이오시밀러 '죠베브네'의 승인을 취득했습니다. 조베브네는 아바스틴의 바이오시밀러로, 동등한 안전성, 효능 및 품질을 보여주면서 환자의 접근성과 경제적 부담을 줄이는 저비용 대체품을 제공합니다. 전이성 대장암에 대한 화학요법 처방과의 병용이 가능하고, 특히 헬스케어 예산이 제약되고 있는 시장에서 표준 치료의 보다 광범위한 보급을 지원합니다.
세계의 화학요법제 시장은 집중되고 있으며, 대기업이 시장에서 사업을 전개하고 있습니다. 2024년 기준에서 시장 주요 10개사의 경쟁사가 시장 전체의 47.10%를 차지했습니다.
목차
제1장 주요 요약
대장암 치료제 : 시장 매력 및 거시경제 환경
제2장 목차
제3장 표 일람
제4장 그림 일람
제5장 보고서 구성
제6장 시장 특징
일반적인 시장 정의
개요
대장암 치료제 시장 정의 및 세분화
시장 세분화 : 암 유형별
대장선암
소화관 카르티노이드 종양
기타 암 유형
시장 세분화 : 약제 분류별
표적요법
면역요법
화학요법
기타 분류
시장 세분화 : 유통 채널별
병원 약국
소매 약국
기타 유통 채널
제7장 주요 시장 동향
바이오시밀러의 혁신이 가져오는 대장암 치료에 대한 접근성 향상 및 비용 절감
BRAF V600E 돌연변이 전이성 대장암에서 제1선택 치료의 진전
진행성 대장암에서의 내성을 극복하기 위한 EGFR 억제제 및 KRAS G12C 표적 약제의 병용 요법
차세대 티로신 키나아제 억제제가 전이성 대장암의 치료 옵션 확대
제8장 세계의 대장암 치료제 성장 분석 및 전략적 분석 프레임워크
세계의 PESTEL 분석
정치적
경제적
소셜
기술적
환경 요인
법적 사항
최종 사용자 분석(B2B)
병원
전문 클리닉
암치료 및 연구센터
재택 치료 환경
외래수술센터(ASC)
세계의 대장암 치료제 시장 : 성장률 분석
시장 성장 실적(2019-2024년)
시장 성장 촉진요인(2019-2024년)
시장 성장 억제요인(2019-2024년)
시장 성장 예측(2024-2029년, 2034년)
예측 성장 요인
정량적 성장 요인
성장 촉진요인
성장 억제요인
세계의 대장암 치료제 시장 : 총 잠재 시장 규모(TAM)
제9장 세계의 대장암 치료제 시장 : 세분화
세계의 대장암 치료제 시장 : 암 유형별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 대장암 치료제 시장 : 약제 분류별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 대장암 치료제 시장 : 유통 채널별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 대장암 치료제 시장 : 한국성 및 절제 가능한 선암(스테이지 0-3) 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 대장암 치료제 시장 : 소화관 카르티노이드 종양 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 대장암 치료제 시장 : 기타 암 유형별 세분화 분석 및 예측(2019-2024년, 2029년, 2034년)
제10장 대장암 치료제 시장 : 지역 및 국가별 분석
세계의 대장암 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2029년, 2034년)
세계의 대장암 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2029년, 2034년)
제11장 아시아태평양 시장
제12장 서유럽 시장
제13장 동유럽 시장
제14장 북미 시장
제15장 남미 시장
제16장 중동 시장
제17장 아프리카 시장
제18장 경쟁 구도 및 기업 프로파일
기업 프로파일
Merck & Co., Inc
Amgen Inc
Bristol Myers Squibb Company
F. Hoffman-La Roche Ltd
Eli Lilly and Company
제19장 기타 주요 기업 및 혁신 기업
Bayer AG
Takeda Pharmaceutical Company
Pfizer Inc.
Sanofi
Taiho Pharmaceutical
Johnson & Johnson
Exelixis
AstraZeneca
Daiichi Sankyo Company Limited
AkesoBio
Arcuc Bioscience
Cardiff Oncology
Shanghai Henlius Biotech
Merus
Sumitomo Pharma
제20장 경쟁 벤치마킹
제21장 경쟁 대시보드
제22장 주요 인수합병(M&A)
Sun Pharmaceutical Industries Ltd.가 Checkpoint Therapeutics 인수
Bristol-Myers Squibb가 Mirati Therapeutics 인수
제23장 대장암 치료제 시장 최근 동향
제24장 기회 및 전략
세계의 대장암 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
세계의 대장암 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
세계의 대장암 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제25장 대장암 치료제 시장 : 결론 및 제안
결론
권고
제품
장소
가격
프로모션
사람들
제26장 부록
AJY
영문 목차
영문목차
Colorectal cancer drugs refer to pharmaceutical treatments developed to prevent, manage, or cure cancer that begins in the colon or rectum. These drugs include various therapeutic approaches designed to target cancer cells, slow disease progression and improve survival rates. They play a crucial role in reducing the global burden of colorectal cancer by enhancing patient outcomes.
The global colorectal cancer drugs market reached a value of nearly $12,951.67 million in 2024, having grown at a compound annual growth rate (CAGR) of 6.74% since 2019. The market is expected to grow from $12,951.67 million in 2024 to $16,885.59 million in 2029 at a rate of 5.45%. The market is then expected to grow at a CAGR of 5.37% from 2029 and reach $21,935.16 million in 2034.
Rising Clinical Trial Activity In Pharma
During the historic period, the colorectal cancer drugs market was mainly driven by the rising clinical trial activity in pharma. An increasing number of clinical studies were registered annually, reflecting a surge in research and development efforts across various therapeutic areas. This uptick in clinical trial activity is indicative of a robust pipeline of potential therapies, signaling a dynamic and expanding pharmaceutical landscape. The growing number of clinical trials also underscores the industry's commitment to advancing medical science and addressing unmet patient needs. Moreover, the expansion of clinical trial activities has fostered greater collaboration among research institutions, healthcare providers and regulatory bodies, enhancing the overall efficiency and effectiveness of the drug development process. For example, according to ClinicalTrials.gov, a US-based government-supported database of clinical studies, in 2023, the Americas had approximately 11,974 registered clinical trials, representing 12.06% of the total trials globally. Therefore, the rising clinical trial activity in pharma significantly contributed to the growth and development of the colorectal cancer drugs market during the historic period.
Biosimilar Innovations Enhancing Accessibility And Reducing Costs In Colorectal Cancer
Companies operating in the colorectal cancer drugs market are developing biosimilars to expand treatment accessibility, lower overall therapy costs and provide affordable alternatives to high-priced biologics, while maintaining equivalent safety, efficacy and quality to the reference drugs. Biosimilars also aim to increase patient adherence by reducing financial barriers and to enable broader adoption of standard-of-care therapies in regions with constrained healthcare budgets. For example, in April 2025, Biocon Biologics, an India-based biopharmaceutical company, received approval from the Food and Drug Administration, a US-based federal agency, for Jobevne, a bevacizumab biosimilar indicated for the treatment of metastatic colorectal cancer and other cancers. Jobevne is a biosimilar to Avastin and demonstrates comparable safety, efficacy and quality, while providing a lower-cost alternative that can improve patient access and affordability. It can be used in combination with chemotherapy regimens for metastatic colorectal cancer, supporting broader adoption of standard-of-care therapies, particularly in markets with constrained healthcare budgets.
The global cs market is concentrated, with large players operating in the market. The top ten competitors in the market made up to 47.10% of the total market in 2024.
Colorectal Cancer Drugs Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global colorectal cancer drugs market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for colorectal cancer drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The colorectal cancer drugs market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider colorectal cancer drugs market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics: - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by cancer type, by class and by distribution channel.
Key Trends: - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis:- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Global Market Size And Growth: - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis: - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation: - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by cancer type, by class and by distribution channel in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size And Growth: - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape: - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies:- Details on the company profiles of other major and innovative companies in the market.
Competitive Benchmarking: - Briefs on the financials comparison between major players in the market.
Competitive Dashboard: - Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions: - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments:- Information on recent developments in the market covered in the report.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for colorectal cancer drugs providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix:- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Cancer Type: Colorectal Adenocarcinoma; Gastrointestinal Carcinoid Tumors; Other Cancer Types
2) By Class: Targeted Therapy; Immunotherapy; Chemotherapy; Other Classes
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
Companies Mentioned: Merck & Co. Inc.; Amgen Inc.; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd.; Eli Lilly & Company.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; colorectal cancer drugs indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1 Executive Summary
1.1 Colorectal Cancer Drugs - Market Attractiveness And Macro Economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Colorectal Cancer Drugs Market Definition And Segmentations
6.4 Market Segmentation By Cancer Type
6.4.1 Colorectal Adenocarcinoma
6.4.2 Gastrointestinal Carcinoid Tumors
6.4.3 Other Cancer Types
6.5 Market Segmentation By Class
6.5.1 Targeted Therapy
6.5.2 Immunotherapy
6.5.3 Chemotherapy
6.5.4 Other Classes
6.6 Market Segmentation By Distribution Channels
6.6.1 Hospital Pharmacies
6.6.2 Retail Pharmacies
6.6.3 Other Distribution Channels
7 Major Market Trends
7.1 Biosimilar Innovations Enhancing Accessibility And Reducing Costs In Colorectal Cancer
7.2 Advancing Frontline Treatment In BRAF V600E-Mutant Metastatic Colorectal Cancer
7.3 Combination Of EGFR Inhibitors With KRAS G12C-Targeted Agents To Overcome Resistance In Advanced Colorectal Cancer
7.4 Next-Generation Tyrosine Kinase Inhibitors Expanding Treatment Options In Metastatic Colorectal Cancer
8 Global Colorectal Cancer Drugs Growth Analysis And Strategic Analysis Framework
8.1 Global: PESTEL Analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Environmental
8.1.6 Legal
8.2 Analysis of End Users (B2B)
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Cancer Treatment and Research Centers
8.2.4 Homecare Settings
8.2.5 Ambulatory Surgical Centers
8.3 Global Colorectal Cancer Drugs Market Growth Rate Analysis
8.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
8.7 Global Colorectal Cancer Drugs Total Addressable Market (TAM)
9 Global Colorectal Cancer Drugs Market Segmentation
9.1 Global Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.4 Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Localized Or Resectable Adenocarcinoma (Stages 0-III), By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.5 Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Gastrointestinal Carcinoid Tumors, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
9.6 Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10 Colorectal Cancer Drugs Market, Regional and Country Analysis
10.1 Global Colorectal Cancer Drugs Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Colorectal Cancer Drugs Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11 Asia-Pacific Market
11.1 Summary
11.2 Market Overview
11.2.1 Region Information
11.2.2 Market Information
11.2.3 Background Information
11.2.4 Government Initiatives
11.2.5 Regulations
11.2.6 Regulatory Bodies
11.2.7 Major Associations
11.2.8 Taxes Levied
11.2.9 Corporate Tax Structure
11.2.10 Investments
11.2.11 Major Companies
11.3 Asia Pacific Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia Pacific Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.6 China Market
11.7 Summary
11.8 Market Overview
11.8.1 Country Information
11.8.2 Market Information
11.8.3 Background Information
11.8.4 Government Initiatives
11.8.5 Regulations
11.8.6 Regulatory Bodies
11.8.7 Major Associations
11.8.8 Taxes Levied
11.8.9 Corporate Tax Structure
11.8.10 Investments
11.8.11 Major Companies
11.9 China Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.10 China Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.12 India Market
11.13 India Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.14 India Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.16 Japan Market
11.17 Summary
11.18 Market Overview
11.18.1 Country Information
11.18.2 Market Information
11.18.3 Background Information
11.18.4 Government Initiatives
11.18.5 Regulations
11.18.6 Regulatory Bodies
11.18.7 Major Associations
11.18.8 Taxes Levied
11.18.9 Corporate Tax Structure
11.18.10 Investments
11.18.11 Major Companies
11.19 Japan Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.20 Japan Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.22 South Korea Market
11.23 Summary
11.24 Market Overview
11.24.1 Country Information
11.24.2 Market Information
11.24.3 Background Information
11.24.4 Government Initiatives
11.24.5 Regulations
11.24.6 Regulatory Bodies
11.24.7 Major Associations
11.24.8 Taxes Levied
11.24.9 Corporate Tax Structure
11.24.10 Investments
11.24.11 Major Companies
11.25 South Korea Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.26 South Korea Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.27 South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.28 Australia Market
11.29 Australia Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.30 Australia Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.31 Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.32 Indonesia Market
11.33 Indonesia Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.34 Indonesia Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
11.35 Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12 Western Europe Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate tax structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Western Europe Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Colorectal Cancer Drugs Market: Country Analysis
12.7 UK Market
12.8 UK Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.19 Italy Market
12.20 Italy Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.21 Italy Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.22 Italy Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.23 Spain Market
12.24 Spain Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.25 Spain Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.26 Spain Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13 Eastern Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Investments
13.2.11 Major companies
13.3 Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.6 Eastern Europe Colorectal Cancer Drugs Market: Country Analysis
13.7 Russia Market
13.8 Russia Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.9 Russia Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
13.10 Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14 North America Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 North America Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Colorectal Cancer Drugs Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
14.9.1 Country Information
14.9.2 Market Information
14.9.3 Background Information
14.9.4 Government Initiatives
14.9.5 Regulations
14.9.6 Regulatory Bodies
14.9.7 Major Associations
14.9.8 Taxes Levied
14.9.9 Corporate Tax Structure
14.9.10 Investments
14.9.11 Major Companies
14.10 USA Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
14.15.1 Country Information
14.15.2 Market Information
14.15.3 Background Information
14.15.4 Government Initiatives
14.15.5 Regulations
14.15.6 Regulatory Bodies
14.15.7 Major Associations
14.15.8 Taxes Levied
14.15.9 Corporate Tax Structure
14.15.10 Investments
14.15.11 Major Companies
14.16 Canada Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15 South America Market
15.1 Summary
15.2 Market Overview
15.2.1 Region Information
15.2.2 Market Information
15.2.3 Background Information
15.2.4 Government Initiatives
15.2.5 Regulations
15.2.6 Regulatory Bodies
15.2.7 Major Associations
15.2.8 Taxes Levied
15.2.9 Corporate Tax Structure
15.2.10 Investments
15.2.11 Major Companies
15.3 South America Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.6 Brazil Market
15.7 Brazil Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.8 Brazil Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16 Middle East Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Investments
16.2.11 Major Companies
16.3 Middle East Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17 Africa Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Investments
17.2.11 Major Companies
17.3 Africa Colorectal Cancer Drugs Market, Segmentation By Cancer Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Colorectal Cancer Drugs Market, Segmentation By Class, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18 Competitive Landscape And Company Profiles
18.1 Company Profiles
18.2 Merck & Co., Inc
18.2.1 Company Overview
18.2.2 Products And Services
18.2.3 Business Strategy
18.2.4 Financial Overview
18.3 Amgen Inc
18.3.1 Company Overview
18.3.2 Products And Services
18.3.3 Business Strategy
18.3.4 Financial Overview
18.4 Bristol Myers Squibb Company
18.4.1 Company Overview
18.4.2 Products And Services
18.4.3 Business Strategy
18.4.4 Financial Overview
18.5 F. Hoffman-La Roche Ltd
18.5.1 Company Overview
18.5.2 Products And Services
18.5.3 Business Strategy
18.5.4 Financial Overview
18.6 Eli Lilly and Company
18.6.1 Company Overview
18.6.2 Products And Services
18.6.3 Financial Overview
19 Other Major And Innovative Companies
19.1 Bayer AG
19.1.1 Company Overview
19.1.2 Products And Services
19.2 Takeda Pharmaceutical Company
19.2.1 Company Overview
19.2.2 Products And Services
19.3 Pfizer Inc.
19.3.1 Company Overview
19.3.2 Products And Services
19.4 Sanofi
19.4.1 Company Overview
19.4.2 Products And Services
19.5 Taiho Pharmaceutical
19.5.1 Company Overview
19.5.2 Products And Services
19.6 Johnson & Johnson
19.6.1 Company Overview
19.6.2 Products And Services
19.7 Exelixis
19.7.1 Company Overview
19.7.2 Products And Services
19.8 AstraZeneca
19.8.1 Company Overview
19.8.2 Products And Services
19.9 Daiichi Sankyo Company Limited
19.9.1 Company Overview
19.9.2 Products And Services
19.10 AkesoBio
19.10.1 Company Overview
19.10.2 Products And Services
19.11 Arcuc Bioscience
19.11.1 Company Overview
19.11.2 Products And Services
19.12 Cardiff Oncology
19.12.1 Company Overview
19.12.2 Products And Services
19.13 Shanghai Henlius Biotech
19.13.1 Company Overview
19.13.2 Products And Services
19.14 Merus
19.14.1 Company Overview
19.14.2 Products And Services
19.15 Sumitomo Pharma
19.15.1 Company Overview
19.15.2 Products And Services
20 Competitive Benchmarking
21 Competitive Dashboard
22 Key Mergers And Acquisitions
22.1 Sun Pharmaceutical Industries Ltd. Acquired Checkpoint Therapeutics
